Collegium Pharmaceutical, Inc. COLL | NASDAQ
|2026-07-13
Company Overview:
10 Year COLL Performance Metrics:
Build Custom Charts
COLL Financials: Earnings, Revenue, Cash Flow, Ebitda, Cash/Debt, Shares Float, etc:
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
Ratios, Profit Margins & Return on Capital:
Projected Future Returns & Dividends for COLL
Based on past 10-year performance, here are COLL growth metrics:
Share price CAGR of +4.75%
Dividend CAGR of +0%
Using COLL CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| COLL (DRIP) | COLL - No DRIP | |
|---|---|---|
| Current Price | $23.80 | $23.80 |
| Start Shares | 420.17 | 420.17 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 420.17 | 420.17 |
| Dividends Payment | $0.00 | $0.00 |
| Annual Dividends | $0 | $0 |
| Yield on cost | 0.00% | 0.00% |
| Share Price | $23.80 | $23.80 |
| Total Dividends | $0 | $0 |
| Final Value | $10,000 | $10,000 |
NOTE: Above numbers are our estimate based on COLL's Dividend and Price CAGR over past 10 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Company Info
Collegium Pharmaceutical, Inc. (COLL) had its IPO on , and is traded on NASDAQ stock exchange.
Collegium Pharmaceutical, Inc. is a specialty biopharmaceutical company focused on developing and commercializing medicines for pain management and attention-deficit/hyperactivity disorder (ADHD). Its current portfolio includes branded prescription products such as Xtampza ER, Belbuca, the Nucynta franchise, Jornay PM, and Symproic, serving patients with complex and chronic medical conditions. The company emphasizes differentiated drug-delivery technology and responsible pain-management therapies, with its business centered on the U.S. market. Collegium Pharmaceutical, Inc. also supports its products through commercial operations, market access, and patient support activities, making it a notable participant in branded specialty pharmaceuticals.
COLL website: https://www.collegiumpharma.com
DCF Model — COLL
FCF is negative or missing for this company (common for banks) — the model discounts EPS instead.
EPS is negative or missing for this company — Simple mode uses free cash flow per share instead.
| Year | FCF | Implied price |
|---|
